Literature DB >> 22387587

Tolerogenic dendritic cells as a target for the therapy of immune thrombocytopenia.

Jinqiu Fu1, Aijun Zhang, Xiuli Ju.   

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disease in which platelets are destroyed by special antiplatelet autoantibodies produced by B cells. Dendritic cells (DCs) are professional antigen-presenting cells involved in humoral immunity and cellular immunity and among them DCs that induce autoimmune tolerance are called tolerogenic DCs (tDCs). As a promising immunotherapeutic strategy for ITP, tDCs have received increasing attention. In this review, we describe the significant role of DCs in regulating autoimmune balances, introduce the manipulation strategies to generate tDCs, summarize recent progress on the experimental application of tDCs for ITP therapy, and finally discuss the perspectives of tolerogenic vaccination for ITP treatment in the clinic.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387587     DOI: 10.1177/1076029612438612

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

1.  Tolerogenic dendritic cells suppress titanium particle-induced inflammation.

Authors:  Wenzhao Wang; Bing Han; Jianan Chen; Huichao Tian; Mingjie Sun; Yunpeng Jiang; Wei Xie
Journal:  Exp Ther Med       Date:  2021-05-03       Impact factor: 2.447

2.  Antigen-specific tolerogenic dendritic cells ameliorate the severity of murine collagen-induced arthritis.

Authors:  Bin Ning; Jianlu Wei; Aijun Zhang; Weiming Gong; Jinqiu Fu; Tanghong Jia; Shang-You Yang
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

Review 3.  Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications.

Authors:  Seungbo Yoo; Sang-Jun Ha
Journal:  Immune Netw       Date:  2016-02-25       Impact factor: 6.303

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.